
Achim Aigner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3726065/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A new player in the game: treatment with antagomiR-21a-5p significantly attenuates histological and echocardiographic effects of experimental autoimmune myocarditis. Cardiovascular Research, 2022, 118, 556-572.	3.8	14
2	STAT3 Enhances Sensitivity of Glioblastoma to Drug-Induced Autophagy-Dependent Cell Death. Cancers, 2022, 14, 339.	3.7	6
3	Balancing Histone Deacetylase (HDAC) Inhibition and Drugâ€likeness: Biological and Physicochemical Evaluation of ClassÂl Selective HDAC Inhibitors. ChemMedChem, 2022, , .	3.2	10
4	Non-viral siRNA transfection of primary mesenchymal stromal cells (MSCs): Assessment of tyrosine-modified PEI and PPI efficacy and biocompatibility. International Journal of Pharmaceutics, 2022, 612, 121359.	5.2	3
5	Amphiphilic Anionic Oligomer-Stabilized Calcium Phosphate Nanoparticles with Prospects in siRNA Delivery via Convection-Enhanced Delivery. Pharmaceutics, 2022, 14, 326.	4.5	6
6	Unmodified and tyrosine-modified polyethylenimines as potential carriers for siRNA: Biophysical characterization and toxicity. International Journal of Pharmaceutics, 2022, 614, 121468.	5.2	8
7	Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2. Frontiers in Bioengineering and Biotechnology, 2022, 10, 801870.	4.1	13
8	Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as Radiosensitizers. Cancers, 2022, 14, 208.	3.7	5
9	Targeted Transposition of Minicircle DNA Using Single-Chain Antibody Conjugated Cyclodextrin-Modified Poly (Propylene Imine) Nanocarriers. Cancers, 2022, 14, 1925.	3.7	1
10	Impact of medication on blood transcriptome reveals off-target regulations of beta-blockers. PLoS ONE, 2022, 17, e0266897.	2.5	1
11	Characterization of Drug Release from Mesoporous SiO2-Based Membranes with Variable Pore Structure and Geometry. Pharmaceutics, 2022, 14, 1184.	4.5	2
12	Therapeutic miR-506-3p Replacement in Pancreatic Carcinoma Leads to Multiple Effects including Autophagy, Apoptosis, Senescence, and Mitochondrial Alterations In Vitro and In Vivo. Biomedicines, 2022, 10, 1692.	3.2	7
13	Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination Therapy. Cells, 2021, 10, 272.	4.1	3
14	Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. Cancers, 2021, 13, 634.	3.7	96
15	The combined disulfide cross-linking and tyrosine-modification of very low molecular weight linear PEI synergistically enhances transfection efficacies and improves biocompatibility. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 161, 56-65.	4.3	16
16	miR24–3p activity after delivery into pancreatic carcinoma cell lines exerts profound tumor-inhibitory effects through distinct pathways of apoptosis and autophagy induction. Cancer Letters, 2021, 503, 174-184.	7.2	10
17	Targeted RNAi of BIRC5/Survivin Using Antibody-Conjugated Poly(Propylene Imine)-Based Polyplexes Inhibits Growth of PSCA-Positive Tumors. Pharmaceutics, 2021, 13, 676.	4.5	13
18	Nucleic acid delivery with extracellular vesicles. Advanced Drug Delivery Reviews, 2021, 173, 89-111.	13.7	48

#	Article	IF	CITATIONS
19	Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression. Journal of Experimental and Clinical Cancer Research, 2021, 40, 214.	8.6	13
20	Drug Delivery by Ultrasound-Responsive Nanocarriers for Cancer Treatment. Pharmaceutics, 2021, 13, 1135.	4.5	55
21	Tyrosine-modified linear PEIs for highly efficacious and biocompatible siRNA delivery in vitro and in vivo. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 36, 102403.	3.3	16
22	Evaluation of Colon-Specific Plasma Nanovesicles as New Markers of Colorectal Cancer. Cancers, 2021, 13, 3905.	3.7	5
23	Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases. Carcinogenesis, 2021, 42, 1475-1484.	2.8	5
24	Tetraspanin 5 (TSPAN5), a Novel Gatekeeper of the Tumor Suppressor DLC1 and Myocardin-Related Transcription Factors (MRTFs), Controls HCC Growth and Senescence. Cancers, 2021, 13, 5373.	3.7	6
25	SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells. International Journal of Molecular Sciences, 2021, 22, 82.	4.1	3
26	Nanoparticles for local delivery of siRNA in lung therapy. Advanced Drug Delivery Reviews, 2021, 179, 114038.	13.7	23
27	Inhibition of PIM2 in liver cancer decreases tumor cell proliferation in2vitro and in2vivo primarily through the modulation of cell cycle progression. International Journal of Oncology, 2020, 56, 448-459.	3.3	12
28	Extracellular vesicle (ECV)-modified polyethylenimine (PEI) complexes for enhanced siRNA delivery in vitro and in vivo. Journal of Controlled Release, 2020, 319, 63-76.	9.9	101
29	Glioblastoma Tissue Slice Tandem-Cultures for Quantitative Evaluation of Inhibitory Effects on Invasion and Growth. Cancers, 2020, 12, 2707.	3.7	6
30	Nanoparticle-complexed antimiRs for inhibiting tumor growth and metastasis in prostate carcinoma and melanoma. Journal of Nanobiotechnology, 2020, 18, 173.	9.1	17
31	Detection of doxorubicin, cisplatin and therapeutic antibodies in formalin-fixed paraffin-embedded human cancer cells. Histochemistry and Cell Biology, 2020, 153, 367-377.	1.7	10
32	Tyrosine-Modification of Polypropylenimine (PPI) and Polyethylenimine (PEI) Strongly Improves Efficacy of siRNA-Mediated Gene Knockdown. Nanomaterials, 2020, 10, 1809.	4.1	17
33	Synthetic circular miR-21 RNA decoys enhance tumor suppressor expression and impair tumor growth in mice. NAR Cancer, 2020, 2, zcaa014.	3.1	12
34	The Role of IncRNAs TAPIR-1 and -2 as Diagnostic Markers and Potential Therapeutic Targets in Prostate Cancer. Cancers, 2020, 12, 1122.	3.7	15
35	SATB1 as oncogenic driver and potential therapeutic target in head & neck squamous cell carcinoma (HNSCC). Scientific Reports, 2020, 10, 8615.	3.3	8
36	Restoration of MARCK enhances chemosensitivity in cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 843-858.	2.5	10

#	Article	IF	CITATIONS
37	Anti-CD3 Antibody Treatment Reduces Scar Formation in a Rat Model of Myocardial Infarction. Cells, 2020, 9, 295.	4.1	10
38	Determination of atomoxetine or escitalopram in human plasma by HPLC: Applications in neuroscience research studies. International Journal of Clinical Pharmacology and Therapeutics, 2020, 58, 426-438.	0.6	14
39	Mono- and Polyassociation Processes of Pentavalent Biotinylated PEI Glycopolymers for the Fabrication of Biohybrid Structures with Targeting Properties. Biomacromolecules, 2019, 20, 3408-3424.	5.4	7
40	Ricin and Ricinus communis in pharmacology and toxicology-from ancient use and "Papyrus Ebers―to modern perspectives and "poisonous plant of the year 2018― Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 1181-1208.	3.0	33
41	Silencing of Neuropilins and GIPC1 in pancreatic ductal adenocarcinoma exerts multiple cellular and molecular antitumor effects. Scientific Reports, 2019, 9, 15471.	3.3	7
42	Design, synthesis and biological evaluation of \hat{I}^2 -peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity. MedChemComm, 2019, 10, 1109-1115.	3.4	11
43	Therapeutic Targeting of Stat3 Using Lipopolyplex Nanoparticle-Formulated siRNA in a Syngeneic Orthotopic Mouse Glioma Model. Cancers, 2019, 11, 333.	3.7	22
44	Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells InÂVitro and InÂVivo. Molecular Therapy - Nucleic Acids, 2019, 16, 272-283.	5.1	17
45	Polymeric Nanoparticles Based on Tyrosine-Modified, Low Molecular Weight Polyethylenimines for siRNA Delivery. Pharmaceutics, 2019, 11, 600.	4.5	24
46	Perspectives, issues and solutions in RNAi therapy: the expected and the less expected. Nanomedicine, 2019, 14, 2777-2782.	3.3	16
47	Sprayâ€Dried Nanoparticleâ€inâ€Microparticle Delivery Systems (NiMDS) for Gene Delivery, Comprising Polyethylenimine (PEI)â€Based Nanoparticles in a Poly(Vinyl Alcohol) Matrix. Small, 2018, 14, e1701810.	10.0	38
48	The Special AT-rich Sequence Binding Protein 1 (SATB1) and its role in solid tumors. Cancer Letters, 2018, 417, 96-111.	7.2	22
49	Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma. Clinical Colorectal Cancer, 2018, 17, e189-e199.	2.3	24
50	Nanoparticle/siRNA-based therapy strategies in glioma: which nanoparticles, which siRNAs?. Nanomedicine, 2018, 13, 89-103.	3.3	28
51	Pharmacokinetic evaluation of a transdermal anastrozole-in-adhesive formulation. Drug Design, Development and Therapy, 2018, Volume 12, 3653-3664.	4.3	13
52	Role of Chemosensory TRP Channels in Lung Cancer. Pharmaceuticals, 2018, 11, 90.	3.8	11
53	Optimized polyethylenimine (PEI)-based nanoparticles for siRNA delivery, analyzed in vitro and in an ex vivo tumor tissue slice culture model. Drug Delivery and Translational Research, 2017, 7, 206-216.	5.8	40
54	The novel MKL target gene myoferlin modulates expansion and senescence of hepatocellular carcinoma. Oncogene, 2017, 36, 3464-3476.	5.9	29

#	Article	IF	CITATIONS
55	Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells. BMC Cancer, 2017, 17, 3.	2.6	12
56	Sustained delivery of siRNA poly- and lipopolyplexes from porous macromer-crosslinked gelatin gels. International Journal of Pharmaceutics, 2017, 526, 178-187.	5.2	15
57	A Poly(Propyleneimine) Dendrimer-Based Polyplex-System for Single-Chain Antibody-Mediated Targeted Delivery and Cellular Uptake of SiRNA. Small, 2017, 13, 1700072.	10.0	39
58	Transfection of primary brain capillary endothelial cells for protein synthesis and secretion of recombinant erythropoietin: a strategy to enable protein delivery to the brain. Cellular and Molecular Life Sciences, 2017, 74, 2467-2485.	5.4	12
59	From the exposome to mechanistic understanding of chemical-induced adverse effects. Environment International, 2017, 99, 97-106.	10.0	146
60	Nanoparticles for radiooncology: Mission, vision, challenges. Biomaterials, 2017, 120, 155-184.	11.4	87
61	Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson's Disease. Molecular Therapy - Nucleic Acids, 2017, 9, 57-68.	5.1	105
62	Liposome-polyethylenimine complexes (DPPC-PEI lipopolyplexes) for therapeutic siRNA delivery in vivo. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 209-218.	3.3	55
63	Tumor tissue slice cultures as a platform for analyzing tissue-penetration and biological activities of nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 112, 45-50.	4.3	16
64	Influence of nanoparticle-mediated transfection on proliferation of primary immune cells in vitro and in vivo. PLoS ONE, 2017, 12, e0176517.	2.5	18
65	Biokinetic datasets of PEI F25-LMW complexed and non-complexed 32P-siRNA within different lung compartments. Data in Brief, 2016, 7, 1175-1178.	1.0	1
66	TRPM7 is a molecular substrate of ATP-evoked P2X7-like currents in tumor cells. Journal of General Physiology, 2016, 147, 467-483.	1.9	14
67	A novel tyrosine-modified low molecular weight polyethylenimine (P10Y) for efficient siRNA delivery in vitro and in vivo. Journal of Controlled Release, 2016, 230, 13-25.	9.9	58
68	Controlled Release Technologies for RNAi Strategies in Regenerative Medicine. , 2016, , 185-210.		1
69	Microparticulate poly(vinyl alcohol) hydrogel formulations for embedding and controlled release of polyethylenimine (PEI)-based nanoparticles. Acta Biomaterialia, 2016, 45, 210-222.	8.3	30
70	Organotypic slice cultures of human gastric and esophagogastric junction cancer. Cancer Medicine, 2016, 5, 1444-1453.	2.8	50
71	A Bifunctional Approach of Immunostimulation and uPAR Inhibition Shows Potent Antitumor Activity inÂMelanoma. Journal of Investigative Dermatology, 2016, 136, 2475-2484.	0.7	9
72	Cationic Lipid-Coated Polyplexes (Lipopolyplexes) for DNA and Small RNA Delivery. Methods in Molecular Biology, 2016, 1445, 187-200.	0.9	7

#	Article	IF	CITATIONS
73	Biokinetic studies of non-complexed siRNA versus nano-sized PEI F25-LMW/siRNA polyplexes following intratracheal instillation into mice. International Journal of Pharmaceutics, 2016, 500, 227-235.	5.2	21
74	Antigen specific immune response in <i>Chlamydia muridarum</i> genital infection is dependent on murine microRNAs-155 and -182. Oncotarget, 2016, 7, 64726-64742.	1.8	22
75	TRPM7 is a molecular substrate of ATP-evoked P2X7-like currents in tumor cells. Journal of Cell Biology, 2016, 213, 21350IA112.	5.2	0
76	Regioselective Ringâ€Opening Polymerization of a Polyhydroxycarboxylic Acid for the Synthesis of a Nanoscale Carrier Material with pHâ€Dependent Stability and Sustained Drug Release. Angewandte Chemie - International Edition, 2015, 54, 6364-6369.	13.8	2
77	Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner. Neoplasia, 2015, 17, 564-573.	5.3	39
78	Organotypic slice cultures of human gastric cancer (GC) and esophagogastric junction adenocarcinoma (AEG): A new technology to study treatment response, resistance, and tumor heterogeneity Journal of Clinical Oncology, 2015, 33, 76-76.	1.6	0
79	Abstract 301: RealTVac, a novel strategy to treat advanced, late-stage tumors with real-time tumor vaccination. , 2015, , .		0
80	Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells. Nature Cell Biology, 2014, 16, 779-791.	10.3	174
81	Nebulization of liposome–polyethylenimine complexes (lipopolyplexes) for DNA or siRNA delivery: Physicochemical properties and biological activity. European Journal of Lipid Science and Technology, 2014, 116, 1195-1204.	1.5	14
82	Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics. Cancer Chemotherapy and Pharmacology, 2014, 73, 827-837.	2.3	24
83	Storage stability of optimal liposome–polyethylenimine complexes (lipopolyplexes) for DNA or siRNA delivery. Acta Biomaterialia, 2014, 10, 2663-2673.	8.3	65
84	A Novel Method for the Assessment of Targeted PEI-Based Nanoparticle Binding Based on a Static Surface Plasmon Resonance System. Analytical Chemistry, 2014, 86, 6827-6835.	6.5	19
85	Colloidal stability of nano-sized particles in the peritoneal fluid: Towards optimizing drug delivery systems for intraperitoneal therapy. Acta Biomaterialia, 2014, 10, 2965-2975.	8.3	58
86	Multiple effects of the special ATâ€rich binding protein 1 (SATB1) in colon carcinoma. International Journal of Cancer, 2014, 135, 2537-2546.	5.1	25
87	Tau Silencing by siRNA in the P301S Mouse Model of Tauopathy. Current Gene Therapy, 2014, 14, 343-351.	2.0	44
88	U1 Adaptors for the Therapeutic Knockdown of the Oncogene Pim-1 Kinase in Glioblastoma. Nucleic Acid Therapeutics, 2013, 23, 264-272.	3.6	9
89	A chorioallantoic membrane model for the determination of anti-angiogenic effects of imatinib. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 711-715.	4.3	19
90	Stimulation of the chemosensory TRPA1 cation channel by volatile toxic substances promotes cell survival of small cell lung cancer cells. Biochemical Pharmacology, 2013, 85, 426-438.	4.4	54

#	Article	IF	CITATIONS
91	Degradable and Biocompatible Poly(<i>N</i> , <i>N</i> -dimethylaminoethyl Methacrylate- <i>co</i>) Tj ETQq1	1 0.784314 4.1	4 rg B T /Overl
92	Functional Role and Therapeutic Potential of the Pim-1 Kinase in Colon Carcinoma. Neoplasia, 2013, 15, 783-IN28.	5.3	84
93	Polyethylenimines for <scp>siRNA</scp> and <scp>miRNA</scp> delivery <i>in vivo</i> . Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2013, 5, 484-501.	6.1	166
94	Biocompatibility and Efficacy of Oligomaltose-Grafted Poly(ethylene imine)s (OM-PEIs) for in Vivo Gene Delivery. Molecular Pharmaceutics, 2013, 10, 4666-4675.	4.6	30
95	Analysis of Transcriptional Regulation of the Human miR-17-92 Cluster; Evidence for Involvement of Pim-1. International Journal of Molecular Sciences, 2013, 14, 12273-12296.	4.1	29
96	The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival. EMBO Molecular Medicine, 2013, 5, 919-934.	6.9	31
97	Depletion of the transcriptional coactivators megakaryoblastic leukaemia 1 and 2 abolishes hepatocellular carcinoma xenograft growth by inducing oncogeneâ€induced senescence. EMBO Molecular Medicine, 2013, 5, 1367-1382.	6.9	45
98	Polymer-Based Delivery of RNA-Based Therapeutics in Ovarian Cancer. Methods in Molecular Biology, 2013, 1049, 443-465.	0.9	3
99	MicroRNAs (miRNAs) in Colorectal Cancer: From Aberrant Expression Towards Therapy. Current Pharmaceutical Design, 2012, 19, 1242-1252.	1.9	32
100	PEI-complexed LNA antiseeds as miRNA inhibitors. RNA Biology, 2012, 9, 1088-1098.	3.1	21
101	The proto-oncogene Pim-1 is a target of miR-33a. Oncogene, 2012, 31, 918-928.	5.9	109
102	Verminderung der Genexpression $ ilde{A}^{1\!\!/}$ ber Ribozym-Targeting. , 2012, , 455-465.		0
103	Therapeutic targeting of the mitotic spindle checkpoint through nanoparticle-mediated siRNA delivery inhibits tumor growth in vivo. Cancer Letters, 2011, 304, 128-136.	7.2	24
104	Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 438-449.	4.3	166
105	Maltose- and maltotriose-modified, hyperbranched poly(ethylene imine)s (OM-PEIs): Physicochemical and biological properties of DNA and siRNA complexes. Journal of Controlled Release, 2011, 149, 146-158.	9.9	101
106	MicroRNA Replacement Therapy for miR-145 and miR-33a Is Efficacious in a Model of Colon Carcinoma. Cancer Research, 2011, 71, 5214-5224.	0.9	358
107	MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs. Journal of Molecular Medicine, 2011, 89, 445-457.	3.9	128
108	Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemotherapy and Pharmacology, 2011, 67, 1157-1166.	2.3	77

#	Article	IF	CITATIONS
109	Anti-tumor effects of fibroblast growth factor-binding protein (FGF-BP) knockdown in colon carcinoma. Molecular Cancer, 2011, 10, 144.	19.2	29
110	RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro-Oncology, 2011, 13, 1074-1089.	1.2	60
111	Targeted CRM197-PEG-PEI/siRNA Complexes for Therapeutic RNAi in Glioblastoma. Pharmaceuticals, 2011, 4, 1591-1606.	3.8	17
112	Liposome–polyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials, 2010, 31, 6892-6900.	11.4	183
113	A sensitive polymerase chain reaction-based method for detection and quantification of metastasis in human xenograft mouse models. Clinical and Experimental Metastasis, 2010, 27, 261-271.	3.3	25
114	Polyethylenimine/small interfering RNAâ€mediated knockdown of vascular endothelial growth factor <i>in vivo</i> exerts antiâ€ŧumor effects synergistically with Bevacizumab. Journal of Gene Medicine, 2010, 12, 287-300.	2.8	95
115	Polyethylenimine (PEI)/siRNA-Mediated Gene Knockdown In Vitro and In Vivo. Methods in Molecular Biology, 2010, 623, 283-297.	0.9	56
116	Critical Role of Gα12 and Gα13 for Human Small Cell Lung Cancer Cell Proliferation <i>In vitro</i> and Tumor Growth <i>In vivo</i> . Clinical Cancer Research, 2010, 16, 1402-1415.	7.0	33
117	CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer. Gut, 2010, 59, 1101-1110.	12.1	93
118	Transkingdom RNA interference (tkRNAi) as a new delivery tool for therapeutic RNA. Expert Opinion on Biological Therapy, 2009, 9, 1533-1542.	3.1	5
119	Nonviral delivery platform for therapeutic RNAi: pegylated siRNA/cationic liposome complexes for targeting of the proto-oncogene bcl-2. Future Oncology, 2009, 5, 13-17.	2.4	8
120	Expression of Pleiotrophin and its Receptors in Human Placenta Suggests Roles in Trophoblast Life Cycle and Angiogenesis. Placenta, 2009, 30, 649-653.	1.5	32
121	In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(–PEG)/siRNA complexes. Toxicology and Applied Pharmacology, 2009, 236, 97-108.	2.8	178
122	Hyperbranched PEI with Various Oligosaccharide Architectures: Synthesis, Characterization, ATP Complexation, and Cellular Uptake Properties. Biomacromolecules, 2009, 10, 1114-1124.	5.4	116
123	In vitro cytotoxic and immunomodulatory profiling of low molecular weight polyethylenimines for pulmonary application. Toxicology in Vitro, 2009, 23, 500-508.	2.4	27
124	Enhanced Antitumorigenic Effects in Glioblastoma on Double Targeting of Pleiotrophin and Its Receptor ALK. Neoplasia, 2009, 11, 145-156.	5.3	55
125	Nanosystems for the Delivery of RNAi. , 2009, , 197-220.		0
126	<i>HMGA2</i> gene is a promising target for ovarian cancer silencing therapy. International Journal of Cancer, 2008, 123, 348-356.	5.1	102

#	Article	IF	CITATIONS
127	The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer, 2008, 59, 12-23.	2.0	138
128	PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNA-induced gene targeting efficacy. Journal of Drug Targeting, 2008, 16, 124-139.	4.4	144
129	Polyethylenimine PEI F25-LMW allows the long-term storage of frozen complexes as fully active reagents in siRNA-mediated gene targeting and DNA delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 29-41.	4.3	72
130	Cellular Delivery In Vivo of siRNA-Based Therapeutics. Current Pharmaceutical Design, 2008, 14, 3603-3619.	1.9	79
131	Tumor-targeting nanosystems for the delivery of siRNA. Nanomedicine, 2007, 2, 569-572.	3.3	3
132	Effects on neurite outgrowth and cell survival of a secreted fibroblast growth factor binding protein upregulated during spinal cord injury. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R775-R783.	1.8	23
133	Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Applied Microbiology and Biotechnology, 2007, 76, 9-21.	3.6	112
134	Nonviral in vivo delivery of therapeutic small interfering RNAs. Current Opinion in Molecular Therapeutics, 2007, 9, 345-52.	2.8	41
135	Gene silencing through RNA interference (RNAi) in vivo: Strategies based on the direct application of siRNAs. Journal of Biotechnology, 2006, 124, 12-25.	3.8	181
136	RNA Interference-Mediated Gene Silencing of Pleiotrophin Through Polyethylenimine-Complexed Small Interfering RNAsIn VivoExerts Antitumoral Effects in Glioblastoma Xenografts. Human Gene Therapy, 2006, 17, 751-766.	2.7	229
137	The fibroblast growth factor-binding protein FGF-BP. International Journal of Biochemistry and Cell Biology, 2006, 38, 1463-1468.	2.8	84
138	A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes. Journal of Controlled Release, 2006, 112, 257-270.	9.9	265
139	Delivery Systems for the Direct Application of siRNAs to Induce RNA Interference (RNAi) In Vivo. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-15.	3.0	100
140	RNA Interference-Mediated Gene Silencing of Pleiotrophin Through Polyethylenimine-Complexed Small Interfering RNAs In Vivo Exerts Antitumoral Effects in Glioblastoma Xenografts. Human Gene Therapy, 2006, .	2.7	0
141	Ribozyme-targeting reveals the rate-limiting role of pleiotrophin in glioblastoma. International Journal of Cancer, 2005, 117, 942-951.	5.1	35
142	Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 2005, 371, 141-151.	3.0	18
143	RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Therapy, 2005, 12, 461-466.	4.5	660
144	Poly(vinyl alcohol) Nanofibers by Electrospinning as a Protein Delivery System and the Retardation of Enzyme Release by Additional Polymer Coatings. Biomacromolecules, 2005, 6, 1484-1488.	5.4	329

#	Article	IF	CITATIONS
145	Stabilization of oligonucleotide–polyethylenimine complexes by freeze-drying: physicochemical and biological characterization. Journal of Controlled Release, 2004, 95, 119-131.	9.9	61
146	Physicochemical and Biological Characterization of Polyethylenimine-graft-Poly(ethylene glycol) Block Copolymers as a Delivery System for Oligonucleotides and Ribozymes. Bioconjugate Chemistry, 2004, 15, 677-684.	3.6	88
147	Differential Regulation of a Fibroblast Growth Factor-Binding Protein during Skin Carcinogenesis and Wound Healing. Neoplasia, 2004, 6, 595-602.	5.3	35
148	Efficiency of polyethylenimines and polyethylenimine-graft-poly (ethylene glycol) block copolymers to protect oligonucleotides against enzymatic degradation. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 57, 427-430.	4.3	41
149	Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. Biochemical and Biophysical Research Communications, 2004, 321, 403-412.	2.1	29
150	Matrix Metalloproteinases 2 and 9 Mediate Epidermal Growth Factor Receptor Transactivation by Gonadotropin-releasing Hormone. Journal of Biological Chemistry, 2003, 278, 47307-47318.	3.4	116
151	Expression and Function of the Receptor Protein Tyrosine Phosphatase ζ and Its Ligand Pleiotrophin in Human Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2003, 62, 1265-1275.	1.7	83
152	Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Annals of Oncology, 2003, 14, 1525-1529.	1.2	49
153	Up-regulation of fibroblast growth factor-binding protein, by beta-catenin during colon carcinogenesis. Cancer Research, 2003, 63, 8085-9.	0.9	34
154	Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients. British Journal of Cancer, 2002, 86, 858-863.	6.4	49
155	Pleiotrophin Signaling through Anaplastic Lymphoma Kinase Is Rate-limiting for Glioblastoma Growth. Journal of Biological Chemistry, 2002, 277, 14153-14158.	3.4	153
156	Immunolocalization of an FGF-binding protein reveals a widespread expression pattern during different stages of mouse embryo development. Histochemistry and Cell Biology, 2002, 117, 1-11.	1.7	40
157	Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Therapy, 2002, 9, 1700-1707.	4.5	97
158	Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo. Oncogene, 2002, 21, 5733-5742.	5.9	35
159	Up-regulation of a fibroblast growth factor binding protein in children with renal diseases. Kidney International, 2001, 59, 1717-1728.	5.2	44
160	An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. International Journal of Cancer, 2001, 92, 510-517.	5.1	65
161	Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene, 2001, 20, 2101-2111.	5.9	53
162	The human papillomavirus (HPV) 16 E6 oncoprotein leads to an increase in gene expression of the angiogenic switch molecule FGF-BP in non-immortalized human keratinocytes. Oncogene, 2001, 20, 7430-7436.	5.9	17

#	Article	IF	CITATIONS
163	Enhancement of Fibroblast Growth Factor (FGF) Activity by an FGF-binding Protein. Journal of Biological Chemistry, 2001, 276, 40247-40253.	3.4	128
164	Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin. Journal of Biological Chemistry, 2001, 276, 16772-16779.	3.4	325
165	ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation. , 2000, 86, 644-651.		28
166	Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol. Toxicology, 2000, 144, 221-228.	4.2	30
167	Rat. Growth Factors, 2000, 18, 51-62.	1.7	21
168	Ribozyme Targeting of Angiogenic Molecules. , 1999, , 423-441.		2
169	A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nature Medicine, 1997, 3, 1137-1140.	30.7	225
170	Transport and Detoxication: Principles, Approaches, and Perspectives for Research on the Blood– Brain Barrier. Angewandte Chemie International Edition in English, 1997, 36, 24-41.	4.4	20